Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05180708 · ClinicalTrials.gov registry record · Phase 3
A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita
A Phase 3 study, sponsored by Palvella Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 87
- Enrollment target
NCT05180708 is a Phase 3 study that has completed, run by Palvella Therapeutics. The registered enrollment target is 87 participants.
The verdict
NCT05180708, a Phase 3 study, has completed, sponsored by Palvella Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 87 participants
- Enrollment target
Study Summary
This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
Interventions
- DRUG Vehicle
- DRUG QTORIN 3.9% rapamycin anhydrous gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-11-29 |
| Est. Completion | 2023-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05180708
The ClinicalTrials.gov registry entry for NCT05180708 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Palvella Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT05180708 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05180708 about?
NCT05180708 is a clinical study titled "A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita". This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.
What is the current status of trial NCT05180708?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 87 participants. The study started on 2021-11-29. Estimated completion is 2023-06-30.
What interventions are being tested in trial NCT05180708?
The interventions under investigation include: Vehicle (DRUG), QTORIN 3.9% rapamycin anhydrous gel (DRUG).
Who is sponsoring clinical trial NCT05180708?
This trial is sponsored by Palvella Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.